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with SLE in Spain. Each selected clinical question werentroduction
enal alterations in patients with systemic lupus erythemato-
us (SLE) worsen their prognosis and quality of life1 but,
dvances in last decades have fortunately allowed to better
nderstand and treat acute kidney complications as well as
hose appear in the course of the disease. However, there is still
 considerable number of resistant and recurrent episodes and
ery disturbing situations such as acute or subacute deterio-
ation of renal function.2 In addition, because of the systemic
ature of SLE, the nephrologists should expand their knowl-
dge to extrarenal manifestations.
The Spanish Ministry of Health recently supported the
evelopment of a Clinical Practice Guideline (CPG) for SLE
anagement. The CPG is part of the Spanish Network of
gencies for Health Technology Assessment in the National
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to lupus nephritis (LN) and extrarenal manifestations in which
nephrologists can be involved are summarized in the present
editorial.3
Methods
The methodology followed to develop this CPG for SLE patients
is detailed in the original publication.3 The group con-
ducted a process to identify and prioritize relevant topics
to be addressed by the CPG, taking into account the rele-
vant inputs from a Delphi consultation to people affectedtos Sanz MA, Trujillo-martín MM. Recomendaciones y sugerencias
 clínica 2015. Nefrologia. 2016;36:333–338.
structured using the PICO format (Patients, Intervention,
Comparison, Outcome). A systematic review of evidence was
produced for each key question. The methodological quality of
vier Espan˜a, S.L.U. This is an open access article under the CC
.
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previous GPCs was assessed with the AGREE II instrument
and included systematic reviews and individual studies were
assessed based on the Scottish Intercollegiate Guidelines Net-
work (SIGN) criteria. The levels of evidence and grades of
recommendations were also set according to SIGN criteria.
For important practical aspects without scientiﬁc evidence
available, good clinical practice recommendations (
√
) were
formulated and agreed by consensus of experts. The expert
group consisted of 10–13 professionals based on the nature
of each recommendation (rheumatology, internal medicine,
hematology, dermatology, immunology, nephrology, gynecol-
ogy, neurology, nursing and hospital pharmacy) (Fig. 1).
This guideline addresses the following principal questions
regarding LN:
Question  n◦ 1.  What  dose  of  steroids  would  be  more
appropriate  for  the  induction  treatment?  Under  what
conditions  mycophenolate  (MF)  would  provide  advantages
over other  drugs?
Summary of evidence:
- Methylprednisolone pulse therapy at a dose of 0.5–0.75 g/day
in three batches has shown similar effectiveness and fewer
side effects than higher doses.4 Level of evidence (LE) 3.
- Initial doses of prednisone not exceeding 30 mg/day
combined with hydroxychloroquine, immunosuppressants
and/or methylprednisolone pulses lead to response rates at
least similar to regimens with higher doses.5,6 LE 1−/2+.
- The accumulated dose and the number of weeks with pred-
nisone dose > 5 mg/day are associated with an increased
toxicity.6 LE 2+.
- Adverse effects of cyclophosphamide (CF) have led to the
search for lower doses and alternative drugs with at least the
same effectiveness. An accumulated dose of CF higher than
8 g increases the risk of ovarian failure. For older patients,
the safety dose is reduced up to approximately 5 g.7 LE 2+.
-  For Hispanics/Latin Americans and African Americans, MF
has shown to be more  effective than CF.8 LE 1+. For induction
therapy, the most commonly used dose of mycophenolate
mofetil (MFM)  in high quality studies is 2 g/day for mild to
moderate NL in Europe and 3 g/day for more  severe ones in
North America.9,10 LE 2+.
Recommendations:
- Pulse therapy with methylprednisolone is suggested in the
more  severe cases, with nephrotic syndrome and/or renal
failure. It’s also suggested as oral prednisone saver. Grade of
Recommendation (GR):
√
- It is suggested to start with doses of oral prednisone not
higher than 30 mg/day. GR:C
- The decrease in prednisone dosages should be quick till
≤5 mg/day. Reaching 5 mg/day around 3 months and not
later than 6 months is recommended. GR:C
- In women older than 30 years or at risk of ovarian fail-
ure, the use of low dose of cyclophosphamide (Euro-Lupus
Nephritis Trial [ELNT] pattern) or choose mycophenolate for
both induction and maintenance treatment is suggested.
GR:C;3 6(4):333–338
- In women of childbearing age who have received cyclophos-
phamide, reaching a cumulative dose higher than 8 g (or 5 g
if older than 30 years), mycophenolate (or azathioprine) is
suggested as ﬁrst-line maintenance treatment in the cur-
rent episode and as induction and maintenance treatment
in successive episodes. GR:C
- If therapeutic non-compliance is suspected, cyclophos-
phamide instead of mycophenolate is suggested. GR:
√
- In Hispanic patients from Latin America and African Amer-
icans, the administration of mycophenolate is suggested.
GR:C
- The recommended dose of MFM in induction treatment is
2–3 g/day or equivalent doses of sodium MF. GR:B
Question  n◦ 2:  What  should  be  the  induction  treatment  for
NL with  acute  kidney  failure?
Summary of evidence: Overall, acute renal failure (ARF) is con-
sidered when an increment of serum creatinine >1.5-fold from
baseline or an increment of 0.3 mg/dl within 48 h with or with-
out oliguria is produced.11
- The incidence of ARF is probably low but unknown or unde-
termined since most large studies have excluded these
patients. Only case studies, case series and retrospective
cohorts are available. ARF is associated with worse prog-
nosis for long-term renal survival.11,12 LE 2+.
- The most common causes of ARF among people with NL,
in addition to traditional ones in general population, are:
extracapillary proliferation, necrotizing vasculitis (ANCA+),
thrombotic microangiopathy and acute tubulointerstitial
nephritis. Authors who have described the presence of
positive ANCAs in NL associated with necrotizing and cres-
centic glomerulonephritis have used prednisolone and CF
for induction treatment.13 LE 2+.
- In patients with mild to moderate ARF (GRF < 60 ml/
min/1.73 m2), the MFM  has shown to be as effective as in
patients with normal GFR.14,15 LE 2+.
- In a post hoc analysis of a clinical trial (CT), patients with
GRF < 30 ml/min responded favorably and without differ-
ences between MFM and CF.16 LE 2+.
- The treatment with CF was effective in patients with GFR
between 25 and 80 ml/min/1.73 m2 although the recovery of
renal function was limited at medium-term.17 LE 1+.
- The pulse steroid therapy has been used in severe cases
of NL with ARF. Doses of 500 mg  for three days may be
sufﬁcient.18 LE 3.
Recommendations:
- The use of CF or MFM is suggested as induction
immunosuppressive agent both in cases of mild to
moderate IRA (GFR > 30 ml/min/1.73 m2) and severe
(GFR < 30 ml/min/1.73 m2). GR:C
- Unless contraindication exists, the treatment with pulse√
steroid therapy is suggested in all cases of NL with ARF. GR:
- In patients with NL and ARF with vasculitis/necrotizing
glomerulonephritis injuries, the induction treatment with
CF is suggested when ANCAs are positive. GR:D
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Tratamiento Nefritis Lupica Clas es III  ó IV ±  V
Con síndróme nefrótico ó IRA Sin síndrome nefrótico ni IRA
6-metil prednisolona 500 mg/dia x 3 dias
Prednisona 30 mg/dia +
Micofenolato 2-3 g/dia (caucasianos y asiáticos; y
preferentemente a hipanos/latinoamericanos/negros)
ó
Ciclofosf amida es quema ELNT-NIH (preferentemente  ante  
sospecha inclumplimiento)
(6 me ses )
Prednisona 30 mg/dia +
Micofenolato 2 -3 g/dia (caucasianos y asiáticos; y 
preferentemente a hipanos/latinoamericanos/negros) 
ó
Ciclofosfamida dosis ELNT-NIH (preferentemente ante sospecha 
inclumplimie nto )
(6 me ses )
Resp eroNatseu spuesta
Prednis ona 5  mg/dia +




Prednis ona reiniciar desde  30  mg/dia  +
Micofenolato 3 g/dia 
ó
Ciclofosfamida esquema ELNT-NIH
Respuesta No respuest a
Prednis ona  5  mg/dia  +
Mic ofenolato 1-2 g/dia 
(5 añ os)
Prednisona 5 mg/dia +
Antic alcineurinicos  ó
Rituximab ó
Triple terapia (P+MF+Tac)
Treatm ent of Lupus Nephrit is  Classes  III or  IV ±  V
With nephrotic  syndrome or  ARF Wi thout  nephrotic syndrome or  ARF
6-Methylp red nisolone  500 mg/day x 3 day s
Prednis one 30  mg/day +
Mycophenolate  2 - 3 g/day ( Caucasians and Asians; and 
preferabl y Hispanics/Latin  Ame ricans/African  Ame ricans )
or
Cyclophosp hami de ELNT-NIH dose  scheme  (preferably when
non compliance is suspected)
(6 months)
Prednis one 30  mg/da y +
Mycophenolate  2 -3 g/day  ( Caucasians and  Asians; and 
preferabl y Hispanics /Latin Americans/African  Americans )
or
Cyclophosphamide ELNT-NIH dose scheme (preferably when 
non compliance is su spected)
(6 months)
Response No response
Prednis one 5  mg/day +
Mycophenolate 1-2 g/day 
or
Azathio prine 2 mg/K g/day
(3 yea rs)
Prednis one restart fr om  30 mg/day  +
Mycophenolate  3 g/day
or
Cyclophosp hami de ELNT-NIH dose  scheme 
Response No response
Prednis one  5  mg/day  +
Mycophenolate 1-2 g/day  
(5 yea rs)
Prednis one  5  mg/day +  Antic alcineurinic or
Rituximab or
Triple therapy (P+MF+Tac)
Fig. 1 – Therapeutic algorithm for severe lupus nephritis [classes III–V]. The choice of immunosuppressive agents should be
adapted to the activity and chronicity indices of biopsy, clinical parameters at presentation, ethnicity and involvement of
organs different from kidney. Abbreviations:  ARF: acute renal failure. MF:  mycophenolate. Tac: tacrolimus. P: prednisone.
ELNT: Eurolupus Nephritis Trial. NIH: National Institute of Health.
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Table 1 – Risk factors for renal recurrence described in
different studies.21,25,27
- Male gender.
- Age < 25–30 years.
- African American ethnicity.
- Arterial hypertension.
- Persistence of altered levels of C4, C3 and anti-DNA.
- Karyorrhexis or extracapillary proliferation.
- Activity index >10.
- Class IV ISN/RPS.
- A previous ﬂare.
- Delay in starting the treatment >5 months.
- Delay in reaching treatment response.
- Partial response versus complete response.Question  n◦ 3.  When  the  maintenance  treatment  should
be suspended?
Summary of evidence: Clinical trials and cohort studies in
which the minimum duration of therapy was 24–36 months
have shown that the incidence of renal ﬂare in NL despite
the immunosuppressive treatment is high, ranging from 12
to 45% in the ﬁrst 2–5 years. From ﬁve years, the occurrence of
renal ﬂares would be progressively smaller and unusual after
10 years of remisión.19–22 LE 1++/1+/2+.
- In proliferative LN, the occurrence of a renal ﬂare is
associated with a worse renal and patient survival.22
Nephritic type is associated with worse renal survival than
nephrotic type.19,23–25 However, in the membranous class,
renal ﬂare does not seem to inﬂuence renal survival.25
LE 2+.
-  Extend the duration of maintenance treatment up to 30
months reduces the risk of early relapse and increases renal
and patient survival.20,26 However, there are no clinical tri-
als directly comparing longer or shorter treatment periods
using the same therapeutic regimen. LE 1+/2+.
- The lupus nephritis activity is usually minimal in advanced
stages of chronic renal failure over 12–24 months.22 LE 3.
- Hydroxychloroquine therapy helps to maintain remission
of LN and slows the progression of kidney failure.27
LE 2+.
-  In patients with prolonged referral interval and without risk
factors for recurrence (Table 1), it seems justiﬁed to consider
the withdrawal of maintenance treatment.21,28 LE 2+.
- In patients at high risk of relapse (Table 1), an extension of
the treatment for more  than ﬁve years or even indeﬁnitely
is proposed unless it’s contraindicated.29 LE 4.
- Before considering treatment withdrawal, it seems justiﬁed
to complete a minimum of 12 months of quiescence.21,28,30
LE 2+.
-  The termination of therapy must be very slowly.21,30 A closemonitoring during the ﬁrst ﬁve years, allowing early detec-
tion and treatment of renal ﬂares, is associated to better
long-term survival.23,31 LE 2+.;3 6(4):333–338
Recommendations:
- Maintenance therapy is recommended for all patients who
have achieved at least a partial response to induction. GR:A
- It is recommended to extend this maintenance therapy for
at least 2–3 years. GR:B
- In patients with frequent recurrences without justiﬁable
cause or risk factors for renal recurrence, it is suggested to
extend maintenance therapy for at least ﬁve years. GR:
√
- When considering the total withdrawal of immunosup-
pressive maintenance treatment, it should not be done
before a period of clinical analytic quiescence shorter than
12 months. GR:C
- The total suspension of maintenance immunosuppressive
therapy should be carried out slowly and progressively. GR:C
- Maintaining the long-term treatment with hydroxychloro-
quine is suggested, provided there are no contraindications
or side effects for it. GR:C
Question  n◦4.  When  a  therapeutic  regimen  is  considered
ineffective?  and  a  situation  as  refractory?  How  to  manage
it?
Summary of evidence: There is no standard deﬁnition for
refractoriness. However, considering the prognostic signiﬁ-
cance of not getting a reduction of baseline proteinuria of
more than 50% at six months or a total proteinuria 1 g/24 h,
the absence of at least partial remission after six months of
treatment has been proposed as the main criterion of inefﬁ-
ciency. Refractoriness is therefore deﬁned as the absence of at
least partial remission after six months of treatment.32,33 LE
4.
- Therapeutic non-compliance is one of the ﬁrst reasons to
be discarded before considering a treatment as ineffective.
This risk should be discussed with patients in their ﬁrst
visits. A suspected non-compliance may be one of the rea-
sons to assess drug levels or to choose in proliferative classes
induction regimens with intravenous CF pulses.33,34 LE 4.
- In refractory patients to standard immunosuppressive regi-
mens (CF o MFM), tacrolimus monotherapy has been used
with success and safety.35 Also in combination with MFM,
in a multi-targeted approach that allows increasing over-
all immunosuppression with fewer individual doses.36,37 LE
2−.
- In refractory patients to standard immunosuppressive regi-
mens, the rituximab has been successfully used as rescue
drug.38,39 LE 2+.
- Several consensus CPGs, such as EULAR/ERAEDTA, eGEAS-
SEMI/SEN and ACR,32,40,41 recommend using rituximab,
calcineurin inhibitors, immunoglobulins or drug combina-
tions in cases of refractory NL without satisfactory response
to the change of the ﬁrst-line treatment (MFM and CFM). LE
GPC.
Recommendations:- We  suggest considering as refractory patients those who  do
not achieve remission at least partial after six months of
treatment. GR:D
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 As a ﬁrst step for refractory LN, ensuring a proper thera-
peutic compliance and verifying that the renal lesions are
reversible is suggested. GR:D
 In patients with LN refractory to cyclophosphamide or
mycophenolate, the change to the other ﬁrst-line drug
(mycophenolate or cyclophosphamide) is suggested. GR:D
 The use of rituximab, calcineurin inhibitors or combinations
of drugs is suggested in cases of unsatisfactory response
to the change in ﬁrst-line therapy (cyclophosphamide and
mycophenolate). GR:D
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